Sannié, member of the patients' consultative group of the French National Agency for Medicines and Health Product Safety, France, for European Patients' Rights Day 2017
The document discusses the increasing role of clinical pharmacists in managing medical devices in healthcare. It notes that medical devices contribute greatly to many surgical and therapeutic procedures. Clinical pharmacists are well-suited to help contain costs related to medical devices through activities like ensuring appropriate device selection and use, consulting on properties and regulations of different classes of devices, and training medical teams. The role of pharmacists in medical device management is expected to grow further given new diagnostic technologies and the reclassification of some products from drugs to devices.
Jan Geissler - How Patient (Advocates) discuss Clinical Research on the Internetpatvocates
"How Patient (Advocates) discuss Clinical Research on the Internet", presented by Jan Geissler (Twitter @jangeissler) at DIA Clinical Forum in The Hague on 9 Oct 2012.
This document discusses the involvement of patients and consumers in the work of the European Medicines Agency (EMA). It outlines how:
1) EMA has increasingly involved patients and consumers since 1995, with over 770 instances of involvement in 2016 across activities like scientific committees, benefit-risk discussions, and guidelines development.
2) Involving patients requires resources from organizations like EURORDIS, including staff time equivalent to 1.5 full-time employees and over 280 days volunteered in 2016 on EMA scientific committees.
3) While patient involvement has grown, there are still barriers like availability of advocates, balancing industry relationships, and integrating patient perspectives in regulatory timelines. Further steps are exploring ways to better
The document discusses HTA processes in France for evaluating new medicines. The French HTA process involves evaluating clinical value (SMR), clinical added value (ASMR), target population size, cost-effectiveness and budget impact. Medicines can receive reimbursement from the national health fund based on these evaluations. The HTA process aims to reward medicines providing real medical progress based on improved efficacy, safety or convenience compared to existing options (ASMR) and being worth their cost (cost-effectiveness).
This report explores important questions about the French healthcare system. How is healthcare innovation assessed in France? To what extent is value for money influencing price negotiations with the pharmaceutical industry? Are national guidelines being adhered to in shaping France’s healthcare delivery?
This document discusses improving patient information and addressing unmet needs. It begins by outlining the vast amount of information patients receive from various sources and via social media. However, not all information is helpful, timely, accessible, or trustworthy. The document then categorizes patients' informational needs into 34 categories for healthcare, 16 for work, and 14 for home life. It also maps which information providers, like patient groups, address which categories. The goal is to better understand patient perspectives and fulfill their diverse informational requirements.
This document discusses improving patient information and addressing unmet needs. It outlines that patients receive information from many sources but it is often not helpful, timely, accessible or trustworthy. A survey found over half of patient groups felt information was inadequate. The document proposes charting patient information needs across healthcare, work and home life, and mapping what information patient groups provide to identify gaps. Improving information requires understanding patients' perspectives.
The document discusses challenges around access to medical devices from patients' perspectives across Europe. It notes a lack of transparency in pricing and reimbursement processes and criteria for medical devices. In Hungary specifically, prior to 2010 the reimbursement system for medical devices was non-transparent without clear criteria or patient involvement. A new regulation in 2010 introduced a point-based system for reimbursement decisions, but there is still no experience with how well it will work.
The document discusses the increasing role of clinical pharmacists in managing medical devices in healthcare. It notes that medical devices contribute greatly to many surgical and therapeutic procedures. Clinical pharmacists are well-suited to help contain costs related to medical devices through activities like ensuring appropriate device selection and use, consulting on properties and regulations of different classes of devices, and training medical teams. The role of pharmacists in medical device management is expected to grow further given new diagnostic technologies and the reclassification of some products from drugs to devices.
Jan Geissler - How Patient (Advocates) discuss Clinical Research on the Internetpatvocates
"How Patient (Advocates) discuss Clinical Research on the Internet", presented by Jan Geissler (Twitter @jangeissler) at DIA Clinical Forum in The Hague on 9 Oct 2012.
This document discusses the involvement of patients and consumers in the work of the European Medicines Agency (EMA). It outlines how:
1) EMA has increasingly involved patients and consumers since 1995, with over 770 instances of involvement in 2016 across activities like scientific committees, benefit-risk discussions, and guidelines development.
2) Involving patients requires resources from organizations like EURORDIS, including staff time equivalent to 1.5 full-time employees and over 280 days volunteered in 2016 on EMA scientific committees.
3) While patient involvement has grown, there are still barriers like availability of advocates, balancing industry relationships, and integrating patient perspectives in regulatory timelines. Further steps are exploring ways to better
The document discusses HTA processes in France for evaluating new medicines. The French HTA process involves evaluating clinical value (SMR), clinical added value (ASMR), target population size, cost-effectiveness and budget impact. Medicines can receive reimbursement from the national health fund based on these evaluations. The HTA process aims to reward medicines providing real medical progress based on improved efficacy, safety or convenience compared to existing options (ASMR) and being worth their cost (cost-effectiveness).
This report explores important questions about the French healthcare system. How is healthcare innovation assessed in France? To what extent is value for money influencing price negotiations with the pharmaceutical industry? Are national guidelines being adhered to in shaping France’s healthcare delivery?
This document discusses improving patient information and addressing unmet needs. It begins by outlining the vast amount of information patients receive from various sources and via social media. However, not all information is helpful, timely, accessible, or trustworthy. The document then categorizes patients' informational needs into 34 categories for healthcare, 16 for work, and 14 for home life. It also maps which information providers, like patient groups, address which categories. The goal is to better understand patient perspectives and fulfill their diverse informational requirements.
This document discusses improving patient information and addressing unmet needs. It outlines that patients receive information from many sources but it is often not helpful, timely, accessible or trustworthy. A survey found over half of patient groups felt information was inadequate. The document proposes charting patient information needs across healthcare, work and home life, and mapping what information patient groups provide to identify gaps. Improving information requires understanding patients' perspectives.
The document discusses challenges around access to medical devices from patients' perspectives across Europe. It notes a lack of transparency in pricing and reimbursement processes and criteria for medical devices. In Hungary specifically, prior to 2010 the reimbursement system for medical devices was non-transparent without clear criteria or patient involvement. A new regulation in 2010 introduced a point-based system for reimbursement decisions, but there is still no experience with how well it will work.
Investigation of the accessibility and affordability of medicines in speciali...Cornelis Jan Diepeveen
The document discusses a study investigating the accessibility and affordability of medicines in specialist medical care in the Netherlands. It provides context on key players in the supply chain and financing of these medicines. The study included interviews, literature reviews, surveys, and data analysis. It examines current expenditures on these medicines, how costs may develop, and ways to better ensure accessibility and affordability. The summary provides high-level information on the purpose, methodology, and focus of the study without copying significant text.
Global HTA and pricing mechanisms
What can we learn about national medicines pricing and procurement?
Led by Janssen UK
Day One, Pop-up University 3, 16.00
PharmaCon2007 Congress, Dubrovnik, Croatia "New Technologies and Trends in Pharmacy, Pharmaceutical Industry and Education" http://www.pharmacon2007.com
Abstract is available at http://www.pharmaconnectme.com
Graham was invited to the weekly seminar series by the Royal Brompton Hospital to deliver a presentation on health economics pertinent to Respiratory medicine. They care for a large number of patients with complex lung diseases at the institution and juggle the varied issues of resource (human, structural or financial). As one of many examples, high cost drugs for treating relatively unusual conditions comes up for debate all too frequently. The audience included consultant physicians, senior and junior trainees, nurses and other allied health professionals.
Date: 7 March 2019
Location: The Royal Brompton, London, UK
This document discusses patient involvement at the Medicines Evaluation Board (MEB) in the Netherlands. It makes three key points:
1. The MEB focuses on involving patients throughout the entire life cycle of a medicinal product to ensure the patient perspective is considered. Meetings are held 3-4 times per year and minutes are published online.
2. Strategies for patient involvement at the MEB include having a board member represent the patient perspective, consulting patient organizations on regulatory decisions and guidelines, and creating an online portal for patients.
3. Eliciting individual patient preferences could help identify subgroups with similar preferences to better tailor regulatory decisions and highlight situations where regulator and patient values differ requiring improved communication.
This document provides an overview of key concepts in health economics. It discusses the definition and scope of health economics, as well as important microeconomic and macroeconomic factors that influence the health sector. Some key methods covered include economic evaluation techniques like cost-effectiveness analysis, cost-benefit analysis, and cost-utility analysis. Health outcomes measures like QALYs and DALYs are also explained. The document aims to introduce foundational ideas around applying economic principles and evaluation to issues of health, healthcare delivery, and resource allocation.
The document discusses the role of patients, healthcare professionals, and academics in the European Medicines Agency's (EMA) process of approving medicines in the European Union. It describes how patients and patient organizations can provide input and expertise at various stages of the medicine development and review process. This includes involvement in scientific committees, evaluation of product information for patients, and review of safety communications. While patient participation has increased in recent years, challenges remain around representation, measuring impact, and ensuring comprehensive training. The EMA also facilitates collaboration with healthcare professionals and academics to enhance regulation and research.
Presentation in the framework of the International Conference "10th anniversary of the Spanish Network of Health Technology Assessment Agencies. Towads patient and public engagement in HTA" Zaragoza 27-28 April 2017
This document outlines the process for providing scientific advice to medicine developers through the European Medicines Agency (EMA). It describes the following key steps:
1. Medicine developers submit questions to EMA regarding their medicine development plans. Experts from EMA and national regulators form teams to address the questions.
2. The teams provide responses and advice to help developers design studies that will generate robust evidence on a medicine's safety and effectiveness. This advice is non-binding and does not guarantee approval.
3. The advice aims to help developers avoid poorly-designed trials and instead generate strong data to support regulatory approval and access for patients. It can also encourage development of needed new medicines.
Pharmacoepidemiology is the study of the use and effects of drugs in large populations. It combines elements of pharmacology and epidemiology to quantify adverse drug events, study drug utilization patterns, and test hypotheses about pharmacological issues. Key aspects of pharmacoepidemiology include observational studies to identify risk factors for adverse outcomes, pharmacovigilance to monitor drug safety, and pharmacoeconomic analyses to evaluate the costs and benefits of drug therapies. Pharmacoepidemiology plays an important role in public health by informing decisions about drug reimbursement, regulation, and optimizing medication use at a population level.
1. The document discusses the influence of pharmaceutical companies on patients through disease awareness campaigns and direct-to-consumer information. It argues that such information is often promotional rather than objective.
2. Recommendations are made to ensure information provided to the public is unbiased and meets consumer rights to high-quality, non-promotional health information. More independent research is also needed to study the impact and costs of disease awareness campaigns.
3. The European Commission's proposal on information to patients aims to distinguish information from promotion but could still allow promotion; it needs stricter rules to avoid unethical practices.
Presentation on Concept and structure of MeTA by Wilbert Bannenberg, MeTA Technical Director during the MeTA Country Sharing Meeting, London, 8 December 2009.
An introduction to medication therapy managementKabito Kiwanuka
Pharmacists: An Untapped Resource: Pharmacists receive more training on the safe, effective and appropriate use of medications than any other healthcare professional
The document discusses the history and development of essential medicines. It outlines key events like the growth of new drugs post-WWII, the thalidomide tragedy of 1960, and the 1978 Alma-Ata declaration which established primary health care and inclusion of essential drugs. The WHO defines essential medicines as those that satisfy the majority of a population's health needs. Selection criteria include disease patterns, treatment facilities, and financial resources. National drug policies aim to ensure appropriate access to and use of essential medicines.
Patient Reported Outcomes (PRO) - Challenge and potential solutions.
Why and how can medical device and pharmaceutical companies, as well as the entire healthcare sector, leverage patient engagement with next-generation ePRO solutions?
Discover our white paper...
This document summarizes research on rethinking hospital pharmacist services through centralized logistics and clinical pharmaceutical care strategies. It finds that centralized logistics systems can reduce drug and medical device costs through bulk purchasing and inventory management. It also finds that incorporating clinical pharmacists into medical teams can improve clinical outcomes and reduce costs through optimizing medication management, avoiding errors, and monitoring drug therapies. The document reviews literature showing pharmacists improving outcomes and reducing costs by 35% when integrated into oncology medical teams. It proposes a new model with pharmacists playing a more active clinical role to help contain healthcare spending while improving patient care.
This document discusses ways to make access to innovative medicines more sustainable in the EU. It suggests the EU take a more comprehensive approach when negotiating medicine prices that considers public and private research contributions, product benefits, healthcare budget and organization impacts, and patent duration. It also recommends compulsory licensing be considered when prices are abnormally high. The role of regulators could be improved by expanding compassionate use programs, aligning regulatory and health technology assessment timelines, and increased post-approval monitoring. The EU should protect solidarity principles, encourage transparency, generalize orphan medicine access mechanisms, and encourage joint procurement to reduce prices.
Regione che vai, cura che trovi (forse). I principali risultati del XVII Rapporto sulle politiche della cronicità realizzato dal Coordinamento nazionale delle Associazioni dei Malati Cronici di Cittadinanzattiva
Investigation of the accessibility and affordability of medicines in speciali...Cornelis Jan Diepeveen
The document discusses a study investigating the accessibility and affordability of medicines in specialist medical care in the Netherlands. It provides context on key players in the supply chain and financing of these medicines. The study included interviews, literature reviews, surveys, and data analysis. It examines current expenditures on these medicines, how costs may develop, and ways to better ensure accessibility and affordability. The summary provides high-level information on the purpose, methodology, and focus of the study without copying significant text.
Global HTA and pricing mechanisms
What can we learn about national medicines pricing and procurement?
Led by Janssen UK
Day One, Pop-up University 3, 16.00
PharmaCon2007 Congress, Dubrovnik, Croatia "New Technologies and Trends in Pharmacy, Pharmaceutical Industry and Education" http://www.pharmacon2007.com
Abstract is available at http://www.pharmaconnectme.com
Graham was invited to the weekly seminar series by the Royal Brompton Hospital to deliver a presentation on health economics pertinent to Respiratory medicine. They care for a large number of patients with complex lung diseases at the institution and juggle the varied issues of resource (human, structural or financial). As one of many examples, high cost drugs for treating relatively unusual conditions comes up for debate all too frequently. The audience included consultant physicians, senior and junior trainees, nurses and other allied health professionals.
Date: 7 March 2019
Location: The Royal Brompton, London, UK
This document discusses patient involvement at the Medicines Evaluation Board (MEB) in the Netherlands. It makes three key points:
1. The MEB focuses on involving patients throughout the entire life cycle of a medicinal product to ensure the patient perspective is considered. Meetings are held 3-4 times per year and minutes are published online.
2. Strategies for patient involvement at the MEB include having a board member represent the patient perspective, consulting patient organizations on regulatory decisions and guidelines, and creating an online portal for patients.
3. Eliciting individual patient preferences could help identify subgroups with similar preferences to better tailor regulatory decisions and highlight situations where regulator and patient values differ requiring improved communication.
This document provides an overview of key concepts in health economics. It discusses the definition and scope of health economics, as well as important microeconomic and macroeconomic factors that influence the health sector. Some key methods covered include economic evaluation techniques like cost-effectiveness analysis, cost-benefit analysis, and cost-utility analysis. Health outcomes measures like QALYs and DALYs are also explained. The document aims to introduce foundational ideas around applying economic principles and evaluation to issues of health, healthcare delivery, and resource allocation.
The document discusses the role of patients, healthcare professionals, and academics in the European Medicines Agency's (EMA) process of approving medicines in the European Union. It describes how patients and patient organizations can provide input and expertise at various stages of the medicine development and review process. This includes involvement in scientific committees, evaluation of product information for patients, and review of safety communications. While patient participation has increased in recent years, challenges remain around representation, measuring impact, and ensuring comprehensive training. The EMA also facilitates collaboration with healthcare professionals and academics to enhance regulation and research.
Presentation in the framework of the International Conference "10th anniversary of the Spanish Network of Health Technology Assessment Agencies. Towads patient and public engagement in HTA" Zaragoza 27-28 April 2017
This document outlines the process for providing scientific advice to medicine developers through the European Medicines Agency (EMA). It describes the following key steps:
1. Medicine developers submit questions to EMA regarding their medicine development plans. Experts from EMA and national regulators form teams to address the questions.
2. The teams provide responses and advice to help developers design studies that will generate robust evidence on a medicine's safety and effectiveness. This advice is non-binding and does not guarantee approval.
3. The advice aims to help developers avoid poorly-designed trials and instead generate strong data to support regulatory approval and access for patients. It can also encourage development of needed new medicines.
Pharmacoepidemiology is the study of the use and effects of drugs in large populations. It combines elements of pharmacology and epidemiology to quantify adverse drug events, study drug utilization patterns, and test hypotheses about pharmacological issues. Key aspects of pharmacoepidemiology include observational studies to identify risk factors for adverse outcomes, pharmacovigilance to monitor drug safety, and pharmacoeconomic analyses to evaluate the costs and benefits of drug therapies. Pharmacoepidemiology plays an important role in public health by informing decisions about drug reimbursement, regulation, and optimizing medication use at a population level.
1. The document discusses the influence of pharmaceutical companies on patients through disease awareness campaigns and direct-to-consumer information. It argues that such information is often promotional rather than objective.
2. Recommendations are made to ensure information provided to the public is unbiased and meets consumer rights to high-quality, non-promotional health information. More independent research is also needed to study the impact and costs of disease awareness campaigns.
3. The European Commission's proposal on information to patients aims to distinguish information from promotion but could still allow promotion; it needs stricter rules to avoid unethical practices.
Presentation on Concept and structure of MeTA by Wilbert Bannenberg, MeTA Technical Director during the MeTA Country Sharing Meeting, London, 8 December 2009.
An introduction to medication therapy managementKabito Kiwanuka
Pharmacists: An Untapped Resource: Pharmacists receive more training on the safe, effective and appropriate use of medications than any other healthcare professional
The document discusses the history and development of essential medicines. It outlines key events like the growth of new drugs post-WWII, the thalidomide tragedy of 1960, and the 1978 Alma-Ata declaration which established primary health care and inclusion of essential drugs. The WHO defines essential medicines as those that satisfy the majority of a population's health needs. Selection criteria include disease patterns, treatment facilities, and financial resources. National drug policies aim to ensure appropriate access to and use of essential medicines.
Patient Reported Outcomes (PRO) - Challenge and potential solutions.
Why and how can medical device and pharmaceutical companies, as well as the entire healthcare sector, leverage patient engagement with next-generation ePRO solutions?
Discover our white paper...
This document summarizes research on rethinking hospital pharmacist services through centralized logistics and clinical pharmaceutical care strategies. It finds that centralized logistics systems can reduce drug and medical device costs through bulk purchasing and inventory management. It also finds that incorporating clinical pharmacists into medical teams can improve clinical outcomes and reduce costs through optimizing medication management, avoiding errors, and monitoring drug therapies. The document reviews literature showing pharmacists improving outcomes and reducing costs by 35% when integrated into oncology medical teams. It proposes a new model with pharmacists playing a more active clinical role to help contain healthcare spending while improving patient care.
This document discusses ways to make access to innovative medicines more sustainable in the EU. It suggests the EU take a more comprehensive approach when negotiating medicine prices that considers public and private research contributions, product benefits, healthcare budget and organization impacts, and patent duration. It also recommends compulsory licensing be considered when prices are abnormally high. The role of regulators could be improved by expanding compassionate use programs, aligning regulatory and health technology assessment timelines, and increased post-approval monitoring. The EU should protect solidarity principles, encourage transparency, generalize orphan medicine access mechanisms, and encourage joint procurement to reduce prices.
Similar to Thomas Sannié, Association francaise des hemophilies (20)
Regione che vai, cura che trovi (forse). I principali risultati del XVII Rapporto sulle politiche della cronicità realizzato dal Coordinamento nazionale delle Associazioni dei Malati Cronici di Cittadinanzattiva
I principali dati del Rapporto annuale sulle politiche della cronicità realizzato da Coordinamento nazionale delle Associazioni dei Malati Cronici di Cittadinanzattiva. Presentazione dei principali dati a cura di Maria Teresa Bressi
La presentazione di Tonino Aceti, coordinatore nazionale del Tribunale per i diritti del malato di Cittadinanzattiva e direttore del Coordinamento nazionale delle Associazioni dei Malati Cronici delle principali proposte contenute nella Relazione 2018.
Arnaud Emerieu, President of the European Social Insurance Platform, BelgiumCittadinanzattiva onlus
The document outlines 5 priority areas for payers' perspectives on access to innovation: 1) Steering R&D to public health needs, 2) Ensuring evidence base for innovation through strengthened health technology assessment, 3) Strengthening national pricing and reimbursement mechanisms in interests of patients, payers and society, 4) Increasing transparency around innovative pharmaceuticals, and 5) Supporting innovation in context of sustainable healthcare systems. It advocates for transparent health technology assessment processes, voluntary collaboration between countries on pricing negotiations, ensuring access to medicines based on proven patient benefit, and promoting transparency around clinical trial data and pharmaceutical prices and expenditures to balance innovation and sustainability of health systems.
The world's population is growing larger, older, and sicker, placing increasing challenges on healthcare systems to expand access to care with finite resources. Chronic diseases now account for 70% of illnesses, and the population over 50 will increase by over 500 million by 2025. Healthcare systems face constraints like aging populations, growing disease burdens, and limited budgets. However, new medical technologies in development and advances in data analytics provide optimism for healthier futures. Key questions remain around how to introduce high-value innovations and make systems more sustainable.
Alessia Squillace, Tribunal for Patients' Rights - A campaign on acces on inn...Cittadinanzattiva onlus
The Tribunale per i diritti del malato di Cittadinanzattiva promotes citizens' rights in health services in Italy with over 10,000 active citizens working out of 330 locations. New drugs for treating Hepatitis C offer a cure and simplify treatment but elevated prices and eligibility criteria limit access for many patients. The organization established a national tutelage program providing information, counseling, and monitoring access to the new drugs which has helped increase funding and prescription centers, expand eligibility criteria, and start over 53,000 patients on treatment, though access remains limited for some groups.
Gottfried Endel, Main Association of Austrian Social Insurance Institutions, ...Cittadinanzattiva onlus
Gottfried Endel, Main Association of Austrian Social Insurance Institutions, Austria for 2017 European Patients' Rights Day in Brussels, "The payers' perspective on access to innovation"
Pamela Mazzocato discusses how lean practices can be used to improve emergency care by reducing waste and inefficiency. Two case studies are described where lean was used: 1) At Danderyd Hospital, lean reduced the time to surgery for hip fractures from 24.8 to 20 hours and increased the percentage of patients operated on within 24 hours from 47% to 83%. 2) At Karolinska University Hospital, lean reduced non-value adding time and variation, increasing the percentage of patients ready to leave the emergency department within 4 hours by up to 29% and decreasing the waiting time for first physician assessment by up to 56%. Lean focuses on continually improving processes to increase value for patients.
Healthy Eating Habits:
Understanding Nutrition Labels: Teaches how to read and interpret food labels, focusing on serving sizes, calorie intake, and nutrients to limit or include.
Tips for Healthy Eating: Offers practical advice such as incorporating a variety of foods, practicing moderation, staying hydrated, and eating mindfully.
Benefits of Regular Exercise:
Physical Benefits: Discusses how exercise aids in weight management, muscle and bone health, cardiovascular health, and flexibility.
Mental Benefits: Explains the psychological advantages, including stress reduction, improved mood, and better sleep.
Tips for Staying Active:
Encourages consistency, variety in exercises, setting realistic goals, and finding enjoyable activities to maintain motivation.
Maintaining a Balanced Lifestyle:
Integrating Nutrition and Exercise: Suggests meal planning and incorporating physical activity into daily routines.
Monitoring Progress: Recommends tracking food intake and exercise, regular health check-ups, and provides tips for achieving balance, such as getting sufficient sleep, managing stress, and staying socially active.
The facial nerve, also known as cranial nerve VII, is one of the 12 cranial nerves originating from the brain. It's a mixed nerve, meaning it contains both sensory and motor fibres, and it plays a crucial role in controlling various facial muscles, as well as conveying sensory information from the taste buds on the anterior two-thirds of the tongue.
At Malayali Kerala Spa Ajman, Full Service includes individualized care for every client. We specifically design each massage session for the individual needs of the client. Our therapists are always willing to adjust the treatments based on the client's instruction and feedback. This guarantees that every client receives the treatment they expect.
By offering a variety of massage services, our Ajman Spa Massage Center can tackle physical, mental, and emotional illnesses. In addition, efficient identification of specific health conditions and designing treatment plans accordingly can significantly enhance the quality of massaging.
At Malayali Kerala Spa Ajman, we firmly believe that everyone should have the option to experience top-quality massage services regularly. To achieve that goal we offer cheap massage services in Ajman.
If you are interested in experiencing transformative massage treatment at Malayali Kerala Spa Ajman, you can use our Ajman Massage Center WhatsApp Number to schedule your next massage session.
Contact @ +971 529818279
Visit @ https://malayalikeralaspaajman.com/
COPD Treatment in Ghatkopar,Mumbai. Dr Kumar DoshiDr Kumar Doshi
Are you or a loved one affected by Chronic Obstructive Pulmonary Disease (COPD)? Discover comprehensive and advanced treatment options with Dr. Kumar Doshi, a preeminent COPD specialist based in Ghatkopar, Mumbai.
Dr. Kumar Doshi is dedicated to delivering the highest standard of care for COPD patients. Whether you are seeking a diagnosis, a second opinion, or exploring new treatment avenues, this presentation will guide you through the exceptional services available at his practice in Ghatkopar, Mumbai.
This particular slides consist of- what is Pneumothorax,what are it's causes and it's effect on body, risk factors, symptoms,complications, diagnosis and role of physiotherapy in it.
This slide is very helpful for physiotherapy students and also for other medical and healthcare students.
Here is a summary of Pneumothorax:
Pneumothorax, also known as a collapsed lung, is a condition that occurs when air leaks into the space between the lung and chest wall. This air buildup puts pressure on the lung, preventing it from expanding fully when you breathe. A pneumothorax can cause a complete or partial collapse of the lung.
Unlocking the Secrets to Safe Patient Handling.pdfLift Ability
Furthermore, the time constraints and workload in healthcare settings can make it challenging for caregivers to prioritise safe patient handling Australia practices, leading to shortcuts and increased risks.
R3 Stem Cell Therapy: A New Hope for Women with Ovarian FailureR3 Stem Cell
Discover the groundbreaking advancements in stem cell therapy by R3 Stem Cell, offering new hope for women with ovarian failure. This innovative treatment aims to restore ovarian function, improve fertility, and enhance overall well-being, revolutionizing reproductive health for women worldwide.
Michigan HealthTech Market Map 2024. Includes 7 categories: Policy Makers, Academic Innovation Centers, Digital Health Providers, Healthcare Providers, Payers / Insurance, Device Companies, Life Science Companies, Innovation Accelerators. Developed by the Michigan-Israel Business Accelerator
The best massage spa Ajman is Chandrima Spa Ajman, which was founded in 2023 and is exclusively for men 24 hours a day. As of right now, our parent firm has been providing massage services to over 50,000+ clients in Ajman for the past 10 years. It has about 8+ branches. This demonstrates that Chandrima Spa Ajman is among the most reasonably priced spas in Ajman and the ideal place to unwind and rejuvenate. We provide a wide range of Spa massage treatments, including Indian, Pakistani, Kerala, Malayali, and body-to-body massages. Numerous massage techniques are available, including deep tissue, Swedish, Thai, Russian, and hot stone massages. Our massage therapists produce genuinely unique treatments that generate a revitalized sense of inner serenely by fusing modern techniques, the cleanest natural substances, and traditional holistic therapists.
International Cancer Survivors Day is celebrated during June, placing the spotlight not only on cancer survivors, but also their caregivers.
CANSA has compiled a list of tips and guidelines of support:
https://cansa.org.za/who-cares-for-cancer-patients-caregivers/
CANSA support - Caring for Cancer Patients' Caregivers
Thomas Sannié, Association francaise des hemophilies
1. European & National Medicines Regulatory
Systems: challenges for an equitable, timely and
suitable access to innovation – 10th May 2017
Round table 3rd sessions
Patient Associations from countries with an
official patients’ committee in the National
Medicines Agency
Thomas Sannié, président
Association française des hémophiles, France
2. 4
Ministry of Health
Haute Autorité
de Sante
Health Professional Unions
Negotiation with
Advice/public health policy
!
Maximum
spending
targets
Pricing
Committee
(CEPS)
PARLIAMENT
Votes laws and
oversees implementation
Advice/p
rice
Advice/reimbursement
National health insurance funds
(compulsory and voluntary)
Source: HAS 2013
ANSM
3. Source: Haute Autorité de Santé 2013
Economical assessment
Medical assessment
CEESP
Transparancy
Committee
CNEMITS
CEPS
4. Involvement?
User/patient representative in ANSM and HAS as member of board/collège (ANSM
and HAS) or working groups or Committees (ANSM and HAS) :
ANSM in charge of the marketing authorization (benefit and risk),
HAS in charge of
- Medical benefit, therapeutic added value and efficacy and safety (CT)
- Efficiency (CEESP)
New opportunity for patient’s organisations: during the assessment of a medicine or a
medical device.
Since November 2016, HAS has asked to patient’s organisations to write contributions
and answer questionnaire:
- impact of the disease or the state of health of the patients/family caregivers, their
perceptions, their quality of life and families ones,
- experience of patients treated with other therapies already avaible,
- experience of patients with the product assessed
Evaluation in september 2017.
CEPS : no user/patient representative member of the committee. Until now, only
hearings.
5. Evaluation patients' involvement in terms of impact and efficacy? What are its
strengths, weaknesses and challenges?
- Challenges : take into account the patient’s objectives and preferences (cultural
thing for Health agencies, methodology), management of potential conflict of
interest, competition between disease, fair pricing (heterogeneity across Europe of
methodologies to fix the price), access to care (weight of the cost of drugs).
- Patients organization, particularly in rare diseases, must provide/must be asked
1. Their analyses about the real burden of a disease (QoL) and real efficacy actual
treatment (among them adverse events) and the role of patients’ education
(experience)
2. evidence from scientific articles, patients registries, patients testimonies
(experience about illness and treatment and real case example), own survey
questionnaires
- It requires an access to data from specific registry/National Health Insurance
Funds and knowledge of the price of medication
- Drug analysis and Health economic analysis require expertise but also
involvement of individuals («lay experts») in the collective decision making process
impacting individuals and public health
Editor's Notes
We won’t describle the hole slide. You only have to remember that National Authority for Health (HAS) advises the Pricing Committee (CEPS) by provinding economical guidance on the most efficient care strategies.
Starting next month, the HAS will have a new mission : the industry will have to submit economic report based on HAS guidelines (see the guideline choices in Methods for economic evaluation) for first listing/application. Under two conditions,
First. Only applies for drugs and medical devices for which the company asks for a high to moderate medical benefit (therapeutic added value -TAV)
Second. the forecasted expenditure must be significant for the health budget (current discussion with the industry, more than 10 million €).
Does it affect the industry working on hemophilia ? CEESP will produce and publish guidance for the Pricing Committee on expected efficiency within 90 days, as well as medical guidance.
Transparency committee => drugs => medical effectiveness,
Medical devices committee (Cnedimts) => technological devices => medical effectiveness
CEESP => expected economic effectiveness => the most efficient care strategies
As patient’s organisation : New procedure (since november 2016) : during the assessment of a medicine or a medical device
this information is published on the HAS website and patient associations have 30 days to submit their contributions to the HAS.
These contributions will be based on a standard questionnaire available on the HAS site.
Association will be able to provide their perspective in a formalised
and collective manner. The contributions will be passed onto the expert members of the various
commissions that assess health products.
What is the purpose?
Formalising this new type of patient contribution to the assessment of health products should provide
the commissions’ experts with a broader view concerning:
> the impact of the disease or the state of health of the patients, their perceptions,
their quality of life (or that of their families),
>the experience of patients treated with therapies other than those assessed,
> the experience of patients with the product assessed (if the patients have experience
using the products or the association knows the results of clinical trials relative to the product)
: quality of life of a pwh with or without treatment, unsafe and safe products). Economists have to understand that the decision making process in HTA, their methodology and if it is necessary, their finding must be challenged. The final decision is the fruitfull results of consultation, debate and argumentation. A patient organisation can/has to play its place.
- second argument : HTA Agencies must ask Patient organization and if not, patients organization need to provide evidence and it is particularly important in rare diseases.
- theird : Patients organization need to have a full access to datas from their national haemophiliac and patient with bleeding disorders registry (in France called FranceCoag) but also from their National Health Insurance Funds (which might be difficult)
- Fourth : Patients organization need to know the price of medications (price of reimbursement and eventually new and lower prices after negotiation between the industry and hospitals)
- Fifth: Public involvement is crucial. Experts must be challenged.
Maximum expenditure threshold